Morgan Stanley’s XBiotech XBIT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $389K | Buy |
165,554
+2,135
| +1% | +$5.16K | ﹤0.01% | 5597 |
|
|
2025
Q4 | $391K | Buy |
163,419
+41,966
| +35% | +$103K | ﹤0.01% | 5639 |
|
|
2025
Q3 | $323K | Buy |
121,453
+35,648
| +42% | +$106K | ﹤0.01% | 5696 |
|
|
2025
Q2 | $255K | Sell |
85,805
-19,692
| -19% | -$57.3K | ﹤0.01% | 5755 |
|
|
2025
Q1 | $342K | Sell |
105,497
-16,893
| -14% | -$58.2K | ﹤0.01% | 5507 |
|
|
2024
Q4 | $483K | Sell |
122,390
-9,299
| -7% | -$63.4K | ﹤0.01% | 5427 |
|
|
2024
Q3 | $1.02M | Buy |
131,689
+31,138
| +31% | +$205K | ﹤0.01% | 5030 |
|
|
2024
Q2 | $517K | Sell |
100,551
-15,776
| -14% | -$122K | ﹤0.01% | 5279 |
|
|
2024
Q1 | $946K | Sell |
116,327
-104,707
| -47% | -$600K | ﹤0.01% | 4974 |
|
|
2023
Q4 | $884K | Buy |
221,034
+133,807
| +153% | +$533K | ﹤0.01% | 5352 |
|
|
2023
Q3 | $359K | Buy |
87,227
+3,331
| +4% | +$16.7K | ﹤0.01% | 5313 |
|
|
2023
Q2 | $498K | Sell |
83,896
-3,411
| -4% | -$15.4K | ﹤0.01% | 5215 |
|
|
2023
Q1 | $301K | Sell |
87,307
-11,050
| -11% | -$41.2K | ﹤0.01% | 5514 |
|
|
2022
Q4 | $345K | Sell |
98,357
-14,801
| -13% | -$50.5K | ﹤0.01% | 5422 |
|
|
2022
Q3 | $409K | Sell |
113,158
-88,640
| -44% | -$417K | ﹤0.01% | 5362 |
|
|
2022
Q2 | $1.13M | Buy |
201,798
+165,382
| +454% | +$1.11M | ﹤0.01% | 4935 |
|
|
2022
Q1 | $315K | Buy |
36,416
+15,428
| +74% | +$155K | ﹤0.01% | 5662 |
|
|
2021
Q4 | $234K | Buy |
20,988
+8,642
| +70% | +$112K | ﹤0.01% | 5985 |
|
|
2021
Q3 | $159K | Sell |
12,346
-645
| -5% | -$10.3K | ﹤0.01% | 6114 |
|
|
2021
Q2 | $215K | Buy |
12,991
+11,411
| +722% | +$194K | ﹤0.01% | 5979 |
|
|
2021
Q1 | $27K | Sell |
1,580
-10,868
| -87% | -$203K | ﹤0.01% | 6614 |
|
|
2020
Q4 | $194K | Buy |
12,448
+6,564
| +112% | +$121K | ﹤0.01% | 5607 |
|
|
2020
Q3 | $112K | Sell |
5,884
-1,540
| -21% | -$26.6K | ﹤0.01% | 5379 |
|
|
2020
Q2 | $102K | Sell |
7,424
-1,022
| -12% | -$14.4K | ﹤0.01% | 5392 |
|
|
2020
Q1 | $89K | Sell |
8,446
-17,132
| -67% | -$279K | ﹤0.01% | 5231 |
|
|
2019
Q4 | $477K | Buy |
25,578
+20,584
| +412% | +$265K | ﹤0.01% | 4951 |
|
|
2019
Q3 | $52K | Buy |
4,994
+4,956
| +13,042% | +$40.4K | ﹤0.01% | 5712 |
|
|
2019
Q2 | $0 | Sell |
38
-8,788
| -100% | -$76.4K | ﹤0.01% | 6759 |
|
|
2019
Q1 | $97K | Buy |
+8,826
| New | +$71.6K | ﹤0.01% | 5411 |
|
|
2018
Q3 | – | Sell |
-13,720
| Closed | -$61K | – | 6820 |
|
|
2018
Q2 | $61K | Sell |
13,720
-28,218
| -67% | -$127K | ﹤0.01% | 5872 |
|
|
2018
Q1 | $224K | Buy |
41,938
+2,473
| +6% | +$11.4K | ﹤0.01% | 5424 |
|
|
2017
Q4 | $155K | Buy |
39,465
+14,992
| +61% | +$63.1K | ﹤0.01% | 5500 |
|
|
2017
Q3 | $107K | Buy |
24,473
+4,531
| +23% | +$21.4K | ﹤0.01% | 5555 |
|
|
2017
Q2 | $94K | Sell |
19,942
-7,003
| -26% | -$67.1K | ﹤0.01% | 5662 |
|
|
2017
Q1 | $444K | Sell |
26,945
-34,694
| -56% | -$454K | ﹤0.01% | 4916 |
|
|
2016
Q4 | $624K | Buy |
61,639
+45,321
| +278% | +$603K | ﹤0.01% | 4789 |
|
|
2016
Q3 | $219K | Buy |
16,318
+282
| +2% | +$4.14K | ﹤0.01% | 4972 |
|
|
2016
Q2 | $336K | Buy |
16,036
+5,627
| +54% | +$81.2K | ﹤0.01% | 4652 |
|
|
2016
Q1 | $98K | Sell |
10,409
-6,739
| -39% | -$55.8K | ﹤0.01% | 5328 |
|
|
2015
Q4 | $186K | Buy |
17,148
+10,268
| +149% | +$131K | ﹤0.01% | 5123 |
|
|
2015
Q3 | $102K | Sell |
6,880
-12,971
| -65% | -$227K | ﹤0.01% | 5418 |
|
|
2015
Q2 | $358K | Buy |
+19,851
| New | +$412K | ﹤0.01% | 4926 |
|
Other funds holding XBIT
VCM
RC
BCM
VFT
Morgan Stanley's XBIT Position: Q1 2026 in Review
Morgan Stanley increased its XBiotech (XBIT) stake by 1.3% in Q1 2026, buying an estimated $5.16K and bringing the position to 165,554 shares worth $389K. The position accounts for ﹤0.01% of the portfolio, ranked #5597.
Morgan Stanley first reported a position in XBIT in Q2 2015 and has held it in 42 quarters since. The position peaked at $1.13M in Q2 2022. 37 funds tracked by Wall St. Rank hold XBIT as of Q1 2026.
- Morgan Stanley held 165,554 shares of XBiotech worth $389K as of Q1 2026.
- Morgan Stanley bought 2,135 XBiotech shares in Q1 2026, an estimated $5.16K.
- XBiotech made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5597 holding.
- Morgan Stanley first reported a position in XBiotech in Q2 2015 and has held it in 42 quarters since.
- Morgan Stanley's XBiotech position peaked at $1.13M in Q2 2022.
- 37 funds tracked by Wall St. Rank held XBiotech as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.